15 Dec Publication of the CellProthera phase I/IIb study design in the ESC Heart Failure Journal
Great news of December 15th 2024!
Discover in open access the innovative study design of our prospective randomised open-label with blinded endpoint (PROBE) adjudication controlled phase I/IIb trial
Roncalli J, Roubille F, Meyer N, Pompilio G, Leroux L, Henon P, et al.
Rationale and design of transendocardial injection of autologous CD34+ cells after automated ex-vivo expansion in post-acute myocardial infarction patients: the phase I/IIb EXCELLENT study. ESC Heart Failure 2024
To know more: doi: 10.1002/ehf2.15124.